Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval

Cantor Fitzgerald raised Ultragenyx Pharma's price target to $39 from $33 and maintained an Overweight rating after FDA approval of FAYUVI (UX111), the first treatment for Sanfilippo syndrome type A. The firm increased its probability-of-success estimate to 100% from 90% and values the MPS IIIA opportunity at roughly $12-$13 per share; the stock traded at $14.50 and was down 37% year to date. The approval offsets, but does not eliminate, concerns following the failed Phase 3 Aspire trial of apazunersen in Angelman syndrome, which prompted other analysts to cut targets.

Analysis

RARE’s rerating hinges less on approval itself than on the conversion of a very small, geographically dispersed patient pool into treated patients. The key swing factors over the next 1-3 months are label breadth, payer coverage criteria, treatment-center readiness, and manufacturing capacity; each can materially delay revenue despite a high nominal price per patient. The prior pipeline setback also makes this asset disproportionately important to RARE’s multiple, increasing both upside from early uptake and downside from any launch friction.

Consensus price targets appear to capitalize a near-clean commercial outcome while giving limited weight to diagnosis leakage, payer prior authorization, and the cost of identifying eligible patients. A better framework is to value the program on treated-patient ramp rather than prevalence: a slow first-year launch would support only a partial recovery in RARE even if the long-term opportunity remains intact. The first independently disclosed reimbursement wins and treated-patient metrics—not additional analyst target changes—are the relevant catalysts.

ABEO may benefit only to the extent its collaboration economics include meaningful royalties, milestones, or manufacturing participation; those terms should be verified before treating it as a read-through. The main falsifier for a RARE long is guidance that implies delayed treatment-center activation, limited reimbursement, or incremental cash burn that shortens the funding runway; those outcomes would likely cap the stock despite regulatory de-risking.

Key Decisions for Investors

• Initiate a starter long RARE at/near $14.50, sized modestly, with a 3-6 month target of $22-25 versus a risk exit below $11 or on evidence of reimbursement/access delays. This underwrites partial commercialization rather than the most bullish $39 sell-side outcome, offering roughly 2:1 upside/downside.
• Add to RARE only after the company discloses initial treated patients, payer coverage, or a credible launch-revenue outlook; these are the data points capable of reducing the commercial-discount rate and expanding the multiple.
• For beta-neutral exposure, express the view as long RARE / short XBI over 3 months. This isolates asset-specific launch execution while reducing exposure to broad biotech risk from rates, risk appetite, or FDA-sector sentiment.
• Do not initiate ABEO solely on this development. Set an alert to review SEC filings or company disclosures for royalty rate, milestone timing, territory rights, and manufacturing economics; absent those details, the financial read-through is not investable.